Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In-Jin Jang

Showing results (51-60 of 292) with videos related to

Pageof 30
Sort By:
Drug Design, Development and Therapy|December 13, 2024
Safety, Tolerability and Pharmacokinetics of Intravenous Sodium Taurodeoxycholate, HY209, a GPCR19 Agonist Inhibiting Inflammasomal ActivationWoo Kyung Chung, Inseung Jeon, In-Jin Jang, et al.
Clinical and Translational Science|December 4, 2021
Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenaseJihyun Kang, Andrew HyoungJin Kim, Inseung Jeon, et al.
Clinical Drug Investigation|October 26, 2013
Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteersJieon Lee, Kwang-Hee Shin, Jung-Ryul Kim, et al.
Clinical Pharmacology in Drug Development|March 1, 2021
Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and TelmisartanKi Young Huh, Sang Won Lee, Si Beum Lee, et al.
Drug Design, Development and Therapy|April 26, 2016
Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjectsSu-Jin Rhee, SeungHwan Lee, Seo Hyun Yoon, et al.
Clinical and Translational Science|December 14, 2022
Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizersWoo Kyung Chung, Inyoung Hwang, Byungwook Kim, et al.
British Journal of Clinical Pharmacology|April 8, 2022
Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjectsJun Gi Hwang, SeungHwan Lee, Wan Huh, et al.
British Journal of Clinical Pharmacology|October 14, 2025
Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjectsSooyoun Lee, Hyun Chul Kim, Young Ran Yoon, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2003
Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urineJoo Youn Cho, Hyeong Seok Lim, Kyung Sang Yu, et al.
Clinical Therapeutics|November 18, 2011
Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteersNamyi Gu, Sojeong Yi, Tae-Eun Kim, et al.
Pageof 30

Showing results (51-60 of 292) with videos related to

Sort By:
Pageof 30
Drug Design, Development and Therapy|December 13, 2024
Safety, Tolerability and Pharmacokinetics of Intravenous Sodium Taurodeoxycholate, HY209, a GPCR19 Agonist Inhibiting Inflammasomal ActivationWoo Kyung Chung, Inseung Jeon, In-Jin Jang, et al.
Clinical and Translational Science|December 4, 2021
Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenaseJihyun Kang, Andrew HyoungJin Kim, Inseung Jeon, et al.
Clinical Drug Investigation|October 26, 2013
Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteersJieon Lee, Kwang-Hee Shin, Jung-Ryul Kim, et al.
Clinical Pharmacology in Drug Development|March 1, 2021
Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and TelmisartanKi Young Huh, Sang Won Lee, Si Beum Lee, et al.
Drug Design, Development and Therapy|April 26, 2016
Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjectsSu-Jin Rhee, SeungHwan Lee, Seo Hyun Yoon, et al.
Clinical and Translational Science|December 14, 2022
Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizersWoo Kyung Chung, Inyoung Hwang, Byungwook Kim, et al.
British Journal of Clinical Pharmacology|April 8, 2022
Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjectsJun Gi Hwang, SeungHwan Lee, Wan Huh, et al.
British Journal of Clinical Pharmacology|October 14, 2025
Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjectsSooyoun Lee, Hyun Chul Kim, Young Ran Yoon, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2003
Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urineJoo Youn Cho, Hyeong Seok Lim, Kyung Sang Yu, et al.
Clinical Therapeutics|November 18, 2011
Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteersNamyi Gu, Sojeong Yi, Tae-Eun Kim, et al.
Pageof 30